Form 4: Cullinan CSO Sells Shares Under Pre-Arranged 10b5-1 Plan

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, sold 1,345 shares of common stock for $10.01 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, Inc. (CGEM), reported a sale of company common stock.
• On December 19, 2025, Michaelson disposed of 1,345 shares of common stock.
• The shares were sold at a weighted average price of $10.01 per share, with individual transactions ranging from $9.99 to $10.09.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan established on August 7, 2025.
• Following this transaction, Michaelson directly beneficially owns 132,635 shares of Cullinan Therapeutics common stock.

Sentiment

Score: 5

Explanation: A neutral score. While an insider sale can be perceived negatively, the execution under a 10b5-1 plan mitigates concerns, indicating a pre-planned personal financial decision rather than a reaction to new company-specific information.

Positives

• The transaction was executed under a pre-established Rule 10b5-1 trading plan, indicating a planned sale rather than a reaction to recent, non-public company events.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the insider's direct ownership in the company, which can sometimes be perceived as a slight negative by investors.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the general implication of an insider reducing their stake, which is mitigated by the 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction is specific to an individual executive and does not directly reflect broader industry trends or competitive dynamics. Insider sales under 10b5-1 plans are common across various industries for personal financial planning.

Comparison to Industry Standards

• This Form 4 filing details a routine insider transaction under a 10b5-1 plan, which is a standard practice for executives to manage their equity holdings while complying with insider trading regulations. There are no specific comparable companies, projects, or results mentioned in this filing to assess against industry benchmarks.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, potentially viewed as a slight negative, but largely mitigated by the 10b5-1 plan, suggesting no immediate impact on company strategy or performance.

Key Dates

Recommendation

The insider sale by the Chief Scientific Officer, Jennifer Michaelson, was conducted under a pre-arranged 10b5-1 plan. This suggests a planned personal financial management decision rather than a reaction to new material information about Cullinan Therapeutics. While any insider sale reduces management's direct stake, the planned nature of the transaction typically lessens its negative signaling impact. Therefore, this specific filing alone does not provide a strong basis for a change in investment thesis, warranting a 'hold' recommendation.

Keywords

Cullinan Therapeutics, CGEM, Jennifer Michaelson, Insider Sale, Form 4, 10b5-1 Plan, Chief Scientific Officer, Stock Transaction